Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Combination Therapies of Hypomethylating Agents for Elderly Patients with Acute Myeloid Leukemia

Combination Therapies of Hypomethylating Agents for Elderly Patients with Acute Myeloid Leukemia AbstractOlder patients with acute myeloid leukemia (AML) are encumbered with poor long-term outcomes due to patient and disease characteristics. Hypomethylating agents (HMAs), acting as DNA methyltransferase (DNMT) inhibitors, have been established as a new treatment option, but they have been associated with relatively low response rates (15%–20% complete remission) when administered separately for treating elderly with AML. However, appropriate combination therapies with decitabine or azacitidine have flourished. The results of randomized trials of various combinations of HMAs with chemotherapy, histone deacetylase inhibitors, monoclonal antibodies, immunomodulatory agents, kinase inhibitors, or bexarotene are summarized. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Acta Haematologica Polonica de Gruyter

Combination Therapies of Hypomethylating Agents for Elderly Patients with Acute Myeloid Leukemia

Acta Haematologica Polonica , Volume 49 (2): 6 – Aug 30, 2018

Loading next page...
 
/lp/de-gruyter/combination-therapies-of-hypomethylating-agents-for-elderly-patients-OVKw8MdLDB
Publisher
de Gruyter
Copyright
© 2018 Polish Society of Hematology and Transfusion Medicine, Insitute of Hematology and Transfusion Medicine. Published by Sciendo
eISSN
2300-7117
DOI
10.2478/ahp-2018-0011
Publisher site
See Article on Publisher Site

Abstract

AbstractOlder patients with acute myeloid leukemia (AML) are encumbered with poor long-term outcomes due to patient and disease characteristics. Hypomethylating agents (HMAs), acting as DNA methyltransferase (DNMT) inhibitors, have been established as a new treatment option, but they have been associated with relatively low response rates (15%–20% complete remission) when administered separately for treating elderly with AML. However, appropriate combination therapies with decitabine or azacitidine have flourished. The results of randomized trials of various combinations of HMAs with chemotherapy, histone deacetylase inhibitors, monoclonal antibodies, immunomodulatory agents, kinase inhibitors, or bexarotene are summarized.

Journal

Acta Haematologica Polonicade Gruyter

Published: Aug 30, 2018

References